Maria Belmonte

Radiation oncology ☢️ resident at Fondazione IRCCS San Gerardo dei Tintori 🇮🇹 @unimib.

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

No Better way to start 2025
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer
A Report from #APCCC24 LINK TO ARTICLE👇👇👇
https://t.co/QL8Kuyhxuj

The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors:

@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore Eric Small Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul Consuelo Buttigliero Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis Susan Halabi Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal Fernando C. Maluf ,
@quimmateo
David Matheson, Mika P. Matikainen , Ray McDermott,
@DrRanaMcKay
Niven Mehra,
@amerseburger
@CaPsurvivorship
Michael J. Morris , Hind Mrabti, Deborah Mukherji
@declangmurphy
Vedang Murthy Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemur
@DrYukselUrun
Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero
@AOmlin

[Federica Ferrario @Fefe_Ferrario]

Our real-world analysis on #SBRT ⚡️ and #oligoprogressive #LungCancer 🫁 is officially published and open access!
▶️TTNT 8 months saves⏳✅

Take a look: https://t.co/ZwNvWWk4n0
Amazing team effort @riccardo_ray @CChissotti @MariaBelmonte95 @valefacc22 @PanizzaDenis @StAr_MCM74

[Stefano Arcangeli @StAr_MCM74]

🤙🏻 Excited and proud of presenting the #ABRUPT trial @ASTRO
🙏 to all 1️⃣-fraction believers who followed me in this fool and amazing project

@CChissotti @Fefe_Ferrario @Raffa_Lucchini @MariaBelmonte95 @riccardo_ray @valefacc22 @PanizzaDenis

[Radiation Oncology University Freiburg @RadOnc_UKF]

#ProstateCancer Symposium @Uniklinik_Fr @degro_ev

[Stefano Arcangeli @StAr_MCM74]

🎬 our paper on 1️⃣-shot⚡️RT for UIR and HR PCa is finally out on @IJROBP

👏kudos to the authors for the team effort!

#ABRUPT

@CChissotti @Fefe_Ferrario @Raffa_Lucchini @MariaBelmonte95 @riccardo_ray
@valefacc22 @PanizzaDenis

https://t.co/jTAytuzgSN

[Katsuaki Maehara 🇯🇵 @KatsuakiMaehara]

🌟 The 9th edition of
TNM Classification for
Lung Cancer 🫁
　 1, January, 2024 〜

[Thomas Zilli @ZilliThomas]

Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity ⁦@Achard_Verane⁩ ⁦@VedangMurthy⁩ ⁦@docpriyamvada⁩ https://t.co/3xlAXqhbpr

[Sofia Paola Bianchi @SofiaBianchi93]

💥Finally the results of our experience in managing uncomplicated painful bone metastases (BM) patients.

Pain response (CR+PR):
✔️62% at 1 month
✔️60% at 3 months.
📌A multidisciplinary approach is paramount to provide a better care to BM patients.

[Paul Sargos @PaulSargos]

@AlbertoBossial on the role of RT in MHSPC, discussing Stampede and Peace 1 results during #Prosca2023.
@GETUG_Unicancer
@OncoAlert @PCaParker

[Federica Ferrario @Fefe_Ferrario]

💥 Proud to present my first manuscript on salvage SBRT for PCa late toxicity and QoL, now in @ctRO_journal 💥

Check out the POPART 🇮🇹multicentric trial https://t.co/1GKdq1u9dD

@StAr_MCM74 @CiroFranzese1 @valefacc22 @MartaScorsetti @PanizzaDenis @MariaBelmonte95 @Raffa_Lucchini

[Maria Belmonte @MariaBelmonte95]

Throwback to Marseille #emuc2023.
It was an honour and a pleasure to share the preliminary results of ABRUPT trial, single dose of 24 Gy on prostate gland is:
✅Feasible
✅Well tolerated
A special thanks to my Professor @StAr_MCM74 and to my coworker and mentor @Raffa_Lucchini .

[Stefano Arcangeli @StAr_MCM74]

Friday night with @unimib ☢️residents in Monza! 💥
What a team!🤩🔝

@SofiaBianchi93 @martina_midulla @MiriamTorrisi @Fefe_Ferrario @CChissotti @MariaBelmonte95 @airo_young

[Icro Meattini @Icro_Meattini]

The Lucerne Toolbox 2 to optimise axillary management for early #breastcancer : a multidisciplinary expert consensus
Just published eClinicalMedicine!
https://t.co/h4PPS0zgZ0
@OncoAlert #OncoAlert

[Federica Ferrario @Fefe_Ferrario]

What a day! Co-chair of #prostateSBRT session and interview by @Accuray #ESTRO2023

[Sofia Paola Bianchi @SofiaBianchi93]

IBA Proton therapy - Power up event @labstelle Wien ✨

It was a pleasure to meet you @LMU_Muenchen Belka Claus

[Federica Ferrario @Fefe_Ferrario]

Multidisciplinary approach is the key 🎯☢️💊🔪
#urooncology #iov

[Thomas Zilli @ZilliThomas]

36.25 Gy/5 fx linac-based prostate SBRT with 32.5 Gy urethra-sparing delivered every-other-day or once-a-week.
Minimal impact on tox and QoL regardless of OTT: 5-yr G2+ GU and GI tox-free survival ~76% and ~90%; 5-yr bRFS >90% https://t.co/I9jx9qyI60